<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/0AFA10E4-F0DB-4281-A331-D4C137E82E62"><gtr:id>0AFA10E4-F0DB-4281-A331-D4C137E82E62</gtr:id><gtr:name>Cellular Systems (Grantham) Limited</gtr:name><gtr:address><gtr:line1>BioCity Nottingham
Pennyfoot Street</gtr:line1><gtr:city>Nottingham</gtr:city><gtr:postCode>NG1 1GF</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0AFA10E4-F0DB-4281-A331-D4C137E82E62" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>0AFA10E4-F0DB-4281-A331-D4C137E82E62</gtr:id><gtr:name>Cellular Systems (Grantham) Limited</gtr:name><gtr:address><gtr:line1>BioCity Nottingham
Pennyfoot Street</gtr:line1><gtr:city>Nottingham</gtr:city><gtr:postCode>NG1 1GF</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>24480.0</gtr:offerGrant><gtr:projectCost>40800.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6BAA32D3-0592-4662-8707-B8FF49287B99"><gtr:id>6BAA32D3-0592-4662-8707-B8FF49287B99</gtr:id><gtr:firstName>Unknown</gtr:firstName><gtr:otherNames>Unknown</gtr:otherNames><gtr:surname>Unknown</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=700534"><gtr:id>D3ACDA13-300B-4FCE-9AC8-96566B99E80B</gtr:id><gtr:title>Market for Campylobacter monitoring / Diagnostic tools - an in depth study</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Market</gtr:grantCategory><gtr:grantReference>700534</gtr:grantReference><gtr:abstractText>Campylobacter is an issue affecting the UK?s general population and its food and agricultural
industries. Over the past 5- 10 years much effort has been made by the government to address
the problem, however it still causes 100+ deaths, 22,000 hospitalisations and over 280,000
reported cases a year. In November, 2014 the Food Standards Agency (FSA) revealed that
70% of birds carried the Campylobacter, with an average of 18% being very heavily
contaminated. This was well publicised by the national media. Both the FSA and the
supermarkets are demanding action to reduce the level of the disease and quickly. The best
solution would be to stem the disease ?at source? but any work in this direction has been
limited by the lack of a quick, accurate and inexpensive detection device. Existing methods
require workers to collect faecal samples on over-socks from the chicken houses, taking a
reading on a Lateral Flow Device, or sending them away to a laboratory for a PCR
(polymerase chain reaction) analysis. Both require manual intervention, are expensive and
slow. This continues to make it very difficult to objectively assess the benefits of any
interventions in a timely or accurate manner. We are developing a ?real time?, early stage
monitoring system, looking at VOCs (volatile organic compounds) detected in chicken
houses. A potential market exists in the UK for 5000 units, however identifying the real
market, which extends beyond this, down the supply chain and forward into retail needs to be
investigated in greater depth. This Proof of Market study, is aimed at identifying the nature of
the market UK and revealing the true beneficiaries, who will pay for a ?real time?
Campylobacter monitor. The goal of the project is to clearly identify how the various
component parts of the poultry industry wish to address this issue and what benefits the ?real
time? monitoring system would offer them.</gtr:abstractText><gtr:fund><gtr:end>2015-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2015-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>24480</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">700534</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>